Trinity team attends Battle Summit to hear how Cycle for Survival funding is helping rare cancer patients

Trinity’s Breanna Liponis and Alyssa Blaize recently attended Battle Summit to hear firsthand from Memorial Sloan Kettering doctors and researchers how Cycle for Survival funding is helping rare cancer patients everywhere. The team heard about important studies, initiatives and clinical trials funded through Cycle for Survival donors and participants for salivary gland cancer, pancreatic neuroendocrine tumors and advanced melanoma, among other areas. In addition, the team heard the latest updates on Loxo Oncology’s TRK fusion inhibitor, larotrectinib, developed with Cycle for Survival funding, and its path to FDA approval. At Trinity Partners, we are proud to support Cycle for Survival to help advance rare cancer research. Learn more about Cycle for Survival: https://bit.ly/2KqaFmI and read more about larotrectinib in our latest whitepaper: https://bit.ly/2lCatD5

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s